Have a feature idea you'd love to see implemented?
Let us know!
ITRM Iterum Therapeutics plc
Price (delayed)
$0.9099
Market cap
$20.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$36.9M
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people
Highlights
ITRM's EPS has soared by 56% YoY and by 25% QoQ
The net income rose by 50% YoY and by 20% QoQ
The debt fell by 33% YoY but it rose by 6% QoQ
ITRM's quick ratio has dropped by 83% year-on-year and by 32% since the previous quarter
Iterum Therapeutics's equity has shrunk by 77% QoQ
Key stats
What are the main financial stats of ITRM
Market
Valuations
Earnings
Shares outstanding
22.71M
Market cap
$20.66M
Enterprise value
$36.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$26.19M
EBITDA
-$25.3M
Free cash flow
-$41.95M
Per share
Balance sheet
Liquidity
EPS
-$2
Free cash flow per share
-$2.53
Book value per share
-$0.66
Revenue per share
$0
TBVPS
$0.86
Total assets
$14.17M
Total liabilities
$25.09M
Debt
$21.25M
Equity
-$10.91M
Working capital
-$3.08M
Debt to equity
-1.95
Current ratio
0.82
Quick ratio
0.7
Net debt/EBITDA
-0.64
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-113.6%
Return on equity
N/A
Return on invested capital
-114.7%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITRM stock price
How has the Iterum Therapeutics stock price performed over time
Intraday
-5.01%
1 week
-13.34%
1 month
-15.75%
1 year
23.53%
YTD
-53.81%
QTD
-16.52%
Financial performance
How have Iterum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.26M
Net income
-$28.34M
Gross margin
N/A
Net margin
N/A
The net income rose by 50% YoY and by 20% QoQ
The operating income has increased by 15% since the previous quarter but it has declined by 11% year-on-year
Growth
What is Iterum Therapeutics's growth rate over time
Valuation
What is Iterum Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ITRM's EPS has soared by 56% YoY and by 25% QoQ
Iterum Therapeutics's equity has shrunk by 77% QoQ
Efficiency
How efficient is Iterum Therapeutics business performance
The ROIC has declined by 32% year-on-year and by 16% since the previous quarter
ITRM's ROA is down by 25% YoY and by 9% QoQ
Dividends
What is ITRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITRM.
Financial health
How did Iterum Therapeutics financials performed over time
The total assets is 44% smaller than the total liabilities
ITRM's quick ratio has dropped by 83% year-on-year and by 32% since the previous quarter
ITRM's current ratio has dropped by 81% year-on-year and by 23% since the previous quarter
The debt to equity has plunged by 144% YoY but it has grown by 40% from the previous quarter
Iterum Therapeutics's equity has shrunk by 77% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.